Article Sidebar

PDF
Date Published: 28/02/2026
Abstract Views: 0
Views PDF: 0
DOI: 10.56535/jmpm.v51i2.1796
Issue
Vol. 51 No. 2 (2026): JOURNAL OF MILITARY PHARMACO-MEDICINE No.2 - 2026
Section
Articles
How to Cite
Nguyen, N. N., Nguyen, T. M. L., Nghiem, T. M. C., Nguyen, L. T., & Bui, K. C. (2026). INHIBITION OF CELL PROLIFERATION AND COLONY-FORMING ABILITY IN hyper-IL-6 GENE-TRANSDUCED COLORECTAL CANCER CELL LINES OF RECOMBINANT sgp130Fc PROTEIN. Journal of Military Pharmaco-medicine, 51(2), 43-52. https://doi.org/10.56535/jmpm.v51i2.1796

INHIBITION OF CELL PROLIFERATION AND COLONY-FORMING ABILITY IN hyper-IL-6 GENE-TRANSDUCED COLORECTAL CANCER CELL LINES OF RECOMBINANT sgp130Fc PROTEIN

Nhu Ngoc Nguyen1,2, Thi Mai Ly Nguyen3, Thi Minh Chau Nghiem3, Linh Toan Nguyen4,5, Khac Cuong Bui4,6,
1 Vietnam Military Medical University
2 175 Military Hospital
3 103 Military Hospital, Vietnam Military Medical University
4 Department of Pathophysiology, Vietnam Military Medical University
5 Postgraduate Department, Vietnam Military Medical University
6 Division of Experimental

Main Article Content

Abstract

Objectives: To evaluate the anti-colorectal cancer effect of hyper-IL-6 gene-transduced cells using conditioned medium from sgp130FcH-transfected HEK cells containing recombinant sgp130Fc protein. Methods: The study was conducted in vitro on human colorectal cancer cell lines HT29 hyper-IL-6 and HCT116 hyper-IL-6 using WST-1 and Crystal Violet assay. Results: Conditioned medium from HEK sgp130FcH cells tended to reduce cell viability after 72 hours of treatment compared to HEK WT and control groups, although this decrease was not statisticaly significant (p > 0.05). However, it significantlly inhibited colony formation, with the strongest effect observed in the HCT116 hyper-IL-6 line (p < 0.001). Conclusion: The recombinant sgp130Fc protein in the conditioned medium shows inhibitory effects on the proliferation and a pronounced reduction of colony-forming ability in IL-6-enhanced colorectal cancer cell lines in vitro.

Keywords

Keywords: Colorectal cancer, conditioned medium containing recombinant sgp130 protein, inhibition, cell proliferation, colony formation, HT29 hyper IL-6, HCT116 hyper IL-6.

Article Details

References

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics 2024. CA: A Cancer Journal for Clinicians. 2024; 74(1):12-49.
2. Hossain MS, Karuniawati H, Jairoun AA, et al. Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022; 14(7):1732.
3. Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: Mechanisms and emerging therapeutics. Trends in Pharmacological Sciences. 2023; 44(4): 222-236.
4. Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Frontiers in Oncology. 2022; 12.
5. Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 Activities in the tumour microenvironment. Part 1. Open Access Macedonian Journal of Medical Sciences. 2019; 7(14):2391-2398.
6. Okugawa Y, Miki C, Toiyama Y, et al. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. British Journal of Cancer. 2010; 103(6):787-795.
7. Rose-John S, Jenkins BJ, Garbers C, et al. Targeting IL-6 trans-signalling: Past, present and future prospects. Nature Reviews Immunology. 2023; 23(10):666-681.
8. Bonomi A, Veglia F, Baldassarre D, et al. Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study. Genes & Immunity. 2010; 21(2):100-108.
9. Hong J, Wang H, Shen G, et al. Recombinant soluble sgp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016; 6:24397.
10. Lin Y, He Z, Ye J, et al. Progress in Understanding the IL-6/STAT3 Pathway in colorectal cancer. OncoTargets and Therapy. 2020; 13:13023-13032.